Joanne Blum, MD, PhD, FACP, physician, Texas Oncology, discusses the combination of fulvestrant and palbociclib (Ibrance) in patients with breast cancer, as well as the synergy fulvestrant has with other CDK4/6 inhibitors.
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen